FN Media Group Presents GlobalInvestmentDaily.com Market Commentary
London – November 30, 2020 – Thousands of years ago, ancient Aztecs may have held the key to the next biotech breakthrough. During ceremonial rituals, they used a special compound they called “the flesh of the gods”…And today, researchers are discovering that this same compound could transform mental healthcare moving forward, sparking an explosion of interest in what some experts project could be a $6.9 billion market by 2027. Mentioned in today’s commentary includes: Pfizer Inc. (NYSE: PFE), Teva Pharmaceutical Industries Limited (NYSE: TEVA), Johnson & Johnson (NYSE: JNJ), AbbVie Inc. (NYSE: ABBV) Subsdiary Allergan, PLC., Merck & Co., Inc. (NYSE: MRK).
It’s already being studied in some of the top medical facilities in the United States, including Johns Hopkins University, where it was found that this chemical was up to 4x more effective in treating depression than typical antidepressants.
This could become one of the greatest transformations in mental health care we’ve seen in decades, with the potential to treat chronic conditions much faster than typical treatments. And one company plowing ahead at the forefront of this breakthrough is Lobe Sciences Ltd. (LOBE; GTSIF).
The Massive Mental Health Market
In 2019, it was estimated that 1 in every 5 Americans lives with a mental illness, according to the National Institute of Mental Health. And that was before the stress and uncertainty of living through a global pandemic
That’s why the market for treating mental health and neurodegenerative disorders is projected to reach a whopping $240 billion by 2026. But the transformative medicine movement could be poised to grab a huge share of that market based on early results.
A study from Johns Hopkins showed that when treating terminal cancer patients with psychedelics to reduce anxiety and depression, showing an incredible 80% success rate upon administering large doses of Psylocibin. And the FDA has even granted “Breakthrough Therapy” status to various psychedelic clinical trials looking to address treatment-resistant depression. But successfully treating trauma has been a longstanding issue in psychiatry.
Each year, an estimated 8 million Americans suffer from PTSD. That’s more than the population of the entire state of Washington. And with about 1 in every 13 people experiencing post-traumatic stress disorder (PTSD) at some point throughout their lifetime, this is a major priority in the mental health field.
Clearly this all leads to a massive market opportunity, with the alternatives on the market leaving many people continuing to struggle. But Lobe Sciences Ltd. (LOBE; GTSIF) has already assembled ingredients to address the trauma and concussion issues head on. And as they look to play a major role in treating these issues with their solutions, they could stand to grab a huge part of this multi-billion dollar market.
Building A Giant Moat in This Booming Industry
As this industry continues to grow, Lobe Sciences Ltd. (LOBE; GTSIF) is planting its flag and staking its corner of the market. With its recent acquisition of the biotech company Eleusian Biosciences in July, Lobe now has 5 provisional patents to its name and counting. 3 of these provisional patents are for the chemical compounds themselves, and the other 2 are for their innovative devices.
The treatments are each focused around pairing these revolutionary substances with an over-the-counter drug, addressing both the head trauma and emotional trauma when experiencing concussions.
In short, the over-the-counter drug N-acetylcysteine (NAC) has already been shown to be effective in treating the head injury portion, according to studies published by the National Institute of Health. And these special compounds would work in combination with NAC, potentially preventing patients from experiencing the emotional trauma that often comes after the injury.
World-Class Team and Connections
Lobe Sciences Ltd. (LOBE; GTSIF) is already extremely undervalued in comparison to many of its competitors, but when you consider that none of these competitors have relationships with universities like Lobe does, it’s plain to see why it is the biotech company to watch in the weeks and months ahead. But it’s not just the relationships outside of the organization that give this opportunity so much promise.
Their CEO, Tom Baird, for example, has led engineering design, strategy, and product management for several companies over his career. That includes his background working for TRW Inc., now Northrop Grumman, a $52 billion company.
They’ve also picked up a valuable asset in Maghsoud Dariani, their new Chief Science Officer. Dariani is the best of both worlds, with both the science smarts and the business savvy, making for a perfect combination for creating a quality product then developing a strategy to grow the business behind it.
He’s also currently the CEO of Semorex, a private company developing therapeutics for cancer. And in his past roles as president and vice president of other impressive biotechs, he’s built an incredible list of achievements.
Big Pharma is Looking To Capitalize On This Industry As Well
Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants. They include the Zoloft brand from Pfizer (PFE). Zoloft is one of the world’s most recognizable antidepressants. The drug works by preventing the movement of serotonin back into nerve endings, essentially making the chemical more available for the body to use. This is important because low levels of serotonin have been linked to depression, anxiety, and even obsessive-compulsive behavior.
Pfizer’s Zoloft set itself apart of the many other brands of SSRIs thanks to its tolerability. In many studies, Zoloft has proven itself a drug with minimal negative side-effects, making it one of the first medicines doctors try for many people suffering with depression.
Teva Pharmaceutical Industries Ltd. (TEVA) is another company that, thanks to its series of aggressive expansion and acquisitions has played a major role in helping patients get the treatment they need. In fact, its focus on generic, non-brand-name, medications has made treatment of depression more affordable than ever. Some of the medications it distributes include escitalopram, a generic version of the widely popular Lexapro, and venlafaxine, which some may recognize as Effexor.
Ketamine, a powerful anesthetic drug, and tranquilizer has also shown immense benefits as a treatment for depression and anxiety in tiny micro-doses. And after years of resistance, the FDA is now approved on a limited basis the first-ever legal Ketamine drug—a nasal spray called Spravato used in treatment-resistant depression.
Spravato, developed by pharmaceutical giant Johnson & Johnson (JNJ), has received widespread praise in the medical community. Not only is the medication the first of its kind, it has also had overwhelmingly positive benefits to the patients utilizing the drug. The drug showed improvement in depression symptoms for periods of time as long as four weeks.
Though patients are not able to use the medicine without direct supervision from a healthcare provider due to the side-effects, the procedure so much has proven to be safe and sustainable in the long run.
The success of Spravato has also piqued the interest of Big Pharma firms. AbbVie Inc. (NYSE: ABBV) Subsdiary Allergan, PLC. (AGN), primarily known for its Botox branded injection, is working to create a ketamine-like injectable depression treatment called Rapastinel. The company acquired the brand when it bought out Naurex for $560 million. While the drug was undergoing testing, it has hit a few snags along the way. Though Rapastinel has since been discontinued, Allergan is already working on a new treatment for depression and bipolar disorder in its drug, VRAYLAR, and it’s already been approved by the FDA for testing.
While ketamine has currently captured the spotlight in the new wave of depression treatments, another compound, MDMA, has also shown promise.
MDMA has a long and strange history dating back to 1912. It was created and patented by Merck & Co. (MRK). Rumor has it that the company was asked to create the medicine as an appetite suppressant for German soldiers before the first World War but was shelved later due to its bizarre side effects. The rumor has since been disproven by an investigation done by Merck which discovered that the drug was developed as a potentially lifesaving blood clot agent. Since Merck’s discovery of the chemical, however, it laid relatively dormant until the 1970s, eventually finding its way into the hands of Alexander Shulgin, a renowned chemist known for his experiments with psychedelic medication.
By. Charlotte Hawthorne
IMPORTANT NOTICE AND DISCLAIMER
PAID ADVERTISEMENT. This article is a paid advertisement. GlobalInvestmentDaily.com and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Lobe Sciences to conduct investor awareness advertising and marketing. Lobe paid the Publisher to produce and disseminate five similar articles and additional banner ads at a rate of sixty thousand US dollars per article. This compensation should be viewed as a major conflict with our ability to be unbiased.
Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur.
This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on interviews with company management, and does not (to the Publisher’s knowledge, as confirmed by Lobe) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.
SHARE OWNERSHIP. The Publisher owns shares and/or stock options of the featured companies and therefore has an additional incentive to see the featured companies’ stock perform well. The Publisher does not undertake any obligation to notify the market when it decides to buy or sell shares of the issuer in the market. The Publisher will be buying and selling shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.
FORWARD LOOKING STATEMENTS. This publication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. The Publisher notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the companies’ actual results of operations. Factors that could cause actual results to differ include, but are not limited to, changing governmental laws and policies impacting the company’s business including the legality of Psilocybin and other psychedelics, the ability of the company to exercise or sell its option to acquire shares of Cowlitz County Cannabis Cultivation or otherwise monetize its interest in Cowlitz, the degree of success with research and development of the company’s medicines and devices, the success of clinical trials, governmental approval or clearance of the company’s medicines and devices, the size and growth of the market for the companies’ products and services, the ability of management to execute its business plan, the continuity of management, the companies’ ability to fund its capital requirements in the near term and long term, pricing pressures, etc.
INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
INTELLECTUAL PROPERTY. GlobalInvestmentDaily.com is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.
DISCLAIMER: GlobalInvestmentDaily.com is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with GlobalInvestmentDaily.com or any company mentioned herein. The commentary, views and opinions expressed in this release by GlobalInvestmentDaily.com are solely those of GlobalInvestmentDaily.com and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Media Contact e-mail: firstname.lastname@example.org U.S. Phone: +1(954)345-0611